Cover Image
Market Research Report

Global Myasthenia Gravis Market Research Report Forecast to 2023

Published by Market Research Future Product code 824898
Published Content info 175 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Myasthenia Gravis Market Research Report Forecast to 2023
Published: March 31, 2019 Content info: 175 Pages
Description

Myasthenia Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis, and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2023

Market analysis

Myasthenia gravis (MG) is an immune system neuromuscular illness, its essential effect incorporates a reduction in the convergence of AChRs on the muscle endplate membrane. North America and Latin America altogether make the biggest commitment to the development of the global myasthenia gravis market. In the meantime, Europe and the Asia Pacific hold the second and third spot regarding value. There has been a significant ascent in the predominance of myasthenia gravis as of late, which prompted a sharp increment in treatment request. The global myasthenia gravis market is anticipated to witness an annual growth rate of 9.61% during the estimated period (2018- 2023).

Market segmentation

The global myasthenia gravis market has been segmented on the basis of its type, diagnosis and treatment, end-user and regional demand. Based on its type, the global myasthenia gravis market is segmented as Congenital myasthenia gravis, Ocular myasthenia gravis, Transient myasthenia gravis, Generalized myasthenia gravis, Others. Based on its diagnosis, the market is bifurcated into Electrodiagnostic testing & imaging and Lab-based test. On the basis of its treatment, the global myasthenia gravis market is divided into Immunosuppressive drugs, Cholinesterase inhibitors, Thymectomy, Plasmapheresis, and intravenous immunoglobulin. Based on its end-user industry, the market is divided into Hospitals and Clinics, Academic and Research organizations, Diagnostic Centers.

Regional analysis

Geographically, the global myasthenia gravis market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

CSL Behring, Medtronic Plc., Baxter, Grifols S.A., Shire, Koninklijke Philips N.V., and Valeant Pharmaceuticals International, Inc, GE Healthcare, Alexion Pharmaceuticals, Inc, Novartis AG, Pfizer Inc., Boston Scientific Corporation, among others are some of the major players in the global myasthenia gravis market.

Table of Contents

Table of Contents

1 Executive Summary

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Assumptions & Limitations
    • 2.3.1 Assumptions
    • 2.3.2 Limitations
  • 2.4 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Rising Research Funding for Myasthenia Gravis
    • 4.2.2 Awareness Programs and Initiatives Taken by Associations
    • 4.2.3 Rising Prevalence of MG
  • 4.3 Restraints
    • 4.3.1 High Cost of Treatment Associated with Myasthenia Gravis
  • 4.4 Opportunities
    • 4.4.1 Strong pipeline
  • 4.5 Market Trends
  • 4.6 Macroeconomic Indicators
  • 4.7 Clinical Trials Data

5 Market Factor Analysis

  • 5.1 Porter's Five Forces Analysis
    • 5.1.1 Bargaining Power of Suppliers
    • 5.1.2 Bargaining Power of Buyers
    • 5.1.3 Threat of New Entrants
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Intensity of Rivalry
  • 5.2 Supply Chain Analysis
    • 5.2.1 R&D
    • 5.2.2 Manufacturing
    • 5.2.3 Distribution
    • 5.2.4 Marketing & Sales
    • 5.2.5 Post-Sales Monitoring
  • 5.3 Pricing Analysis

6 Global Myasthenia Gravis Market, By Type

  • 6.1 Introduction
  • 6.2 Ocular Myasthenia Gravis
  • 6.3 Congenital Myasthenia Gravis
  • 6.4 Generalized Myasthenia Gravis
  • 6.5 Transient Myasthenia Gravis

7 Global Myasthenia Gravis Market, By Diagnosis & Treatment

  • 7.1 Introduction
  • 7.2 Diagnosis & Treatment
  • 7.3 Diagnosis
  • 7.4 Treatment

8 Global Myasthenia Gravis Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Centers
  • 8.4 Academic & Research Organizations

9 Global Myasthenia Gravis Market, By Region

  • 9.1 Introduction
  • 9.2 The Americas
    • 9.2.1 North America
      • 9.2.1.1 U.S
      • 9.2.1.2 Canada
    • 9.2.2 South America
  • 9.3 Europe
    • 9.3.1 Western Europe
      • 9.3.1.1 Germany
      • 9.3.1.2 France
      • 9.3.1.3 UK
      • 9.3.1.4 Italy
      • 9.3.1.5 Spain
      • 9.3.1.6 Rest of Western Europe
      • 9.3.1.7 Eastern Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 JAPAN
    • 9.4.3 Australia
    • 9.4.4 INDIA
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 The Middle East & Africa
  • 9.6 Middle East
  • 9.7 AFRICA

10 Competitive Landscape

  • 10.1 Introduction

11 Company Profile

  • 11.1 Alexion Pharmaceuticals, Inc
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 Key Developments
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Strategy
  • 11.2 GE Healthcare
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products/Services Offered
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategy
  • 11.3 Pfizer Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products/Services Offering
    • 11.3.4 Key Developments
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Strategy
  • 11.4 Novartis AG
    • 11.4.1 Company Overview
    • 11.4.2 Products/Services Offered
    • 11.4.3 Key Developments
    • 11.4.4 SWOT Analysis
    • 11.4.5 Key Strategy
  • 11.5 F. Hoffmann-La Roche AG
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered
    • 11.5.4 Key Developments
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Strategy
  • 11.6 CSL Behring
    • 11.6.1 Financial Overview
    • 11.6.2 Products/Services Offered
    • 11.6.3 Key Developments
    • 11.6.4 SWOT Analysis
    • 11.6.5 Key Strategy
  • 11.7 Boston Scientific Corporation
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Strategy
  • 11.8 Baxter
    • 11.8.1 Company Overview
    • 11.8.2 Company Overview
    • 11.8.3 Products/Services Offered
    • 11.8.4 SWOT Analysis
    • 11.8.5 Key Developments
    • 11.8.6 Key strategy
  • 11.9 Grifols S.A.
    • 11.9.1 Company Overview
    • 11.9.2 Financial Overview
    • 11.9.3 Products/Services Offered
    • 11.9.4 Key Developments
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Strategy
  • 11.1 Medtronic Plc
    • 11.10.1 Company Overview
    • 11.10.2 Financial Overview
    • 11.10.3 Products/Services Offered
    • 11.10.4 Key Developments
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Strategy
  • 11.11 Koninklijke Philips N.V.
    • 11.11.1 Company Overview
    • 11.11.2 Financial Overview
    • 11.11.3 Products/Services Offered
    • 11.11.4 Key Developments
    • 11.11.5 SWOT Analysis
    • 11.11.6 Key Strategy
  • 11.12 Shire
    • 11.12.1 Company Overview
    • 11.12.2 Financial Overview
    • 11.12.3 Products/Services Offered
    • 11.12.4 Key Developments
    • 11.12.5 SWOT Analysis
    • 11.12.6 Key Strategy
  • 11.13 Valeant Pharmaceuticals International, Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Financial Overview
    • 11.13.3 Products/Services Offered
    • 11.13.4 Key Developments
    • 11.13.5 SWOT Analysis
    • 11.13.6 Key Strategy

12 Appendix

  • 12.1 Discussion Blue Print
Back to Top